Literature DB >> 15992576

Differential binding properties of [3H]dextrorphan and [3H]MK-801 in heterologously expressed NMDA receptors.

K T LePage1, J E Ishmael, C M Low, S F Traynelis, T F Murray.   

Abstract

The N-methyl-D-aspartate receptor (NMDAR) antagonists: MK-801, phencyclidine and ketamine are open-channel blockers with limited clinical value due to psychotomimetic effects. Similarly, the psychotomimetic effects of the dextrorotatory opioids, dextromethorphan and its metabolite dextrorphan, derive from their NMDAR antagonist actions. Differences in the use dependency of blockade, however, suggest that the binding sites for MK-801 and dextrorphan are distinct. In the absence of exogenous glutamate and glycine, the rate of association of [3H]MK-801 with wild-type NR1-1a/NR2A receptors was considerably slower than that for [3H]dextrorphan. Glutamate individually, and in the presence of the co-agonist glycine, had substantial effects on the specific binding of [3H]MK-801, while the binding of [3H]dextrorphan was not affected. Mutation of residues N616 and A627 in the NR1 subunit had a profound effect on [3H]MK-801 binding affinity, while that of [3H]dextrorphan was unaltered. In contrast, NR1 residues, W611 and N812, were critical for specific binding of [3H]dextrorphan to NR1-1a/NR2A complexes with no corresponding influence on that of [3H]MK-801. Thus, [3H]dextrorphan and [3H]MK-801 have distinct molecular determinants for high-affinity binding. The ability of [3H]dextrorphan to bind to a closed channel, moreover, indicates that its recognition site is shallower in the ion channel domain than that of MK-801 and may be associated with the extracellular vestibule of the NMDAR.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15992576      PMCID: PMC4654417          DOI: 10.1016/j.neuropharm.2005.01.029

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  41 in total

1.  Mutation of a glutamate receptor motif reveals its role in gating and delta2 receptor channel properties.

Authors:  K Kohda; Y Wang; M Yuzaki
Journal:  Nat Neurosci       Date:  2000-04       Impact factor: 24.884

Review 2.  The glutamate receptor ion channels.

Authors:  R Dingledine; K Borges; D Bowie; S F Traynelis
Journal:  Pharmacol Rev       Date:  1999-03       Impact factor: 25.468

3.  Quantitative analysis of the structural requirements for blockade of the N-methyl-D-aspartate receptor at the phencyclidine binding site.

Authors:  R T Kroemer; E Koutsilieri; P Hecht; K R Liedl; P Riederer; J Kornhuber
Journal:  J Med Chem       Date:  1998-01-29       Impact factor: 7.446

4.  Two blocking sites of amino-adamantane derivatives in open N-methyl-D-aspartate channels.

Authors:  A Sobolevsky; S Koshelev
Journal:  Biophys J       Date:  1998-03       Impact factor: 4.033

5.  Biochemical evidence for the co-association of three N-methyl-D-aspartate (NMDA) R2 subunits in recombinant NMDA receptors.

Authors:  L M Hawkins; P L Chazot; F A Stephenson
Journal:  J Biol Chem       Date:  1999-09-17       Impact factor: 5.157

6.  Molecular design of the N-methyl-D-aspartate receptor binding site for phencyclidine and dizolcipine.

Authors:  A V Ferrer-Montiel; W Sun; M Montal
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

7.  Identification by mutagenesis of a Mg(2+)-block site of the NMDA receptor channel.

Authors:  H Mori; H Masaki; T Yamakura; M Mishina
Journal:  Nature       Date:  1992-08-20       Impact factor: 49.962

8.  Pharmacological characterization of heterodimeric NMDA receptors composed of NR 1a and 2B subunits: differences with receptors formed from NR 1a and 2A.

Authors:  D R Lynch; J J Lawrence; S Lenz; N J Anegawa; M Dichter; D B Pritchett
Journal:  J Neurochem       Date:  1995-04       Impact factor: 5.372

9.  High affinity [3H]dextrorphan binding in rat brain is localized to a noncompetitive antagonist site of the activated N-methyl-D-aspartate receptor-cation channel.

Authors:  P H Franklin; T F Murray
Journal:  Mol Pharmacol       Date:  1992-01       Impact factor: 4.436

10.  Structure of the NMDA receptor channel M2 segment inferred from the accessibility of substituted cysteines.

Authors:  T Kuner; L P Wollmuth; A Karlin; P H Seeburg; B Sakmann
Journal:  Neuron       Date:  1996-08       Impact factor: 17.173

View more
  11 in total

Review 1.  Glutamate receptor ion channels: structure, regulation, and function.

Authors:  Stephen F Traynelis; Lonnie P Wollmuth; Chris J McBain; Frank S Menniti; Katie M Vance; Kevin K Ogden; Kasper B Hansen; Hongjie Yuan; Scott J Myers; Ray Dingledine
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

2.  Timosaponin derivative YY-23 acts as a non-competitive NMDA receptor antagonist and exerts a rapid antidepressant-like effect in mice.

Authors:  Qi Zhang; Fei Guo; Zhi-wen Fu; Bing Zhang; Cheng-gang Huang; Yang Li
Journal:  Acta Pharmacol Sin       Date:  2015-12-21       Impact factor: 6.150

3.  Synergism between arrhythmia and hyperhomo-cysteinemia in structural heart disease.

Authors:  Srikanth Givvimani; Natia Qipshidze; Neetu Tyagi; Paras K Mishra; Utpal Sen; Suresh C Tyagi
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2011-05-29

4.  Dextromethorphan in Cough Syrup: The Poor Man's Psychosis.

Authors:  Bridgette Martinak; Ramy A Bolis; Jeffrey Ryne Black; Rachel E Fargason; Badari Birur
Journal:  Psychopharmacol Bull       Date:  2017-09-15

5.  Subunit-specific mechanisms and proton sensitivity of NMDA receptor channel block.

Authors:  Shashank M Dravid; Kevin Erreger; Hongjie Yuan; Katherine Nicholson; Phuong Le; Polina Lyuboslavsky; Antoine Almonte; Ernest Murray; Cara Mosely; Jeremy Barber; Adam French; Robert Balster; Thomas F Murray; Stephen F Traynelis
Journal:  J Physiol       Date:  2007-02-15       Impact factor: 5.182

Review 6.  Novel NMDA receptor modulators: an update.

Authors:  Rose M Santangelo; Timothy M Acker; Sommer S Zimmerman; Brooke M Katzman; Katie L Strong; Stephen F Traynelis; Dennis C Liotta
Journal:  Expert Opin Ther Pat       Date:  2012-09-26       Impact factor: 6.674

Review 7.  NMDA receptors in clinical neurology: excitatory times ahead.

Authors:  Lorraine V Kalia; Suneil K Kalia; Michael W Salter
Journal:  Lancet Neurol       Date:  2008-08       Impact factor: 44.182

8.  The human NMDA receptor GluN2AN615K variant influences channel blocker potency.

Authors:  Katie F M Marwick; Paul A Skehel; Giles E Hardingham; David J A Wyllie
Journal:  Pharmacol Res Perspect       Date:  2019-06-20

9.  Pharmacology and therapeutic potential of sigma(1) receptor ligands.

Authors:  E J Cobos; J M Entrena; F R Nieto; C M Cendán; E Del Pozo
Journal:  Curr Neuropharmacol       Date:  2008-12       Impact factor: 7.363

10.  GRIN2A mutation and early-onset epileptic encephalopathy: personalized therapy with memantine.

Authors:  Tyler Mark Pierson; Hongjie Yuan; Eric D Marsh; Karin Fuentes-Fajardo; David R Adams; Thomas Markello; Gretchen Golas; Dimitre R Simeonov; Conisha Holloman; Anel Tankovic; Manish M Karamchandani; John M Schreiber; James C Mullikin; Cynthia J Tifft; Camilo Toro; Cornelius F Boerkoel; Stephen F Traynelis; William A Gahl
Journal:  Ann Clin Transl Neurol       Date:  2014-03-01       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.